Medicamen Biotech Limited

NSEI:MEDICAMEQ Voorraadrapport

Marktkapitalisatie: ₹6.9b

Medicamen Biotech Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Medicamen Biotech heeft een totaal eigen vermogen van ₹2.0B en een totale schuld van ₹308.2M, wat de schuld-eigenvermogensverhouding op 15.4% brengt. De totale activa en totale passiva bedragen respectievelijk ₹2.9B en ₹875.7M. De EBIT Medicamen Biotech is ₹115.6M waardoor de rentedekking 2.8 is. Het heeft contanten en kortetermijnbeleggingen van ₹147.9M.

Belangrijke informatie

15.4%

Verhouding schuld/eigen vermogen

₹308.17m

Schuld

Rente dekkingsratio2.8x
Contant₹147.86m
Aandelen₹2.00b
Totaal verplichtingen₹875.67m
Totaal activa₹2.95b

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively

Jul 04
These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively

Recent updates

Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce

Sep 28
Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce

Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Sep 03
Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00

Aug 16
Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00

These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively

Jul 04
These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively

What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You

May 21
What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You

More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%

Mar 17
More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%

Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Sep 13
Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 19
Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems

There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price

Dec 03
There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹1.6B ) MEDICAMEQ } overtreffen de korte termijn passiva ( ₹845.6M ).

Langlopende schulden: De kortetermijnactiva MEDICAMEQ ( ₹1.6B ) overtreffen de langetermijnschulden ( ₹30.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 8% ) MEDICAMEQ wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van MEDICAMEQ is de afgelopen 5 jaar gestegen van 13.4% naar 15.4%.

Schuldendekking: De operationele kasstroom van MEDICAMEQ is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: De rentebetalingen van MEDICAMEQ op haar schulden worden niet goed gedekt door EBIT ( 2.8 x dekking).

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y